Market News & Trends
Cristal Therapeutics Highlights Proprietary CriPec Nanomedicine Platform & Promising Data
Cristal Therapeutics recently announced the publication of three articles on CriPec-based nanomedicines in Nano Today, Journal of Controlled Release, and Biomaterials. The publications are co-authored…
Vaccinex Announces Initiation of Phase III Clinical Trial for Huntington’s Disease
Vaccinex, Inc. recently announced it has initiated a Phase II clinical trial to assess the safety, tolerability, and efficacy of anti-semaphorin 4D antibody VX15/2503 (VX15)…
PDC*line Pharma Receives Advanced-Therapy Medicinal Product Classification for New Class of Therapeutic Cancer Vaccines
PDC*line Pharma recently announced that PDC*vac, its new class of therapeutic cancer vaccines based on a line of Plasmacytoid Dendritic Cells (PDC*line), was granted Advanced-Therapy…
ONL Therapeutics Provides Update on Novel Photoreceptor Protection Platform
ONL Therapeutics, Inc. recently provided an update on the company’s ongoing drug development program to block the programmed cell death (apoptosis) of photoreceptors. Death of…
LDC to Collaborate With Johnson & Johnson to Identify & Accelerate Innovative Drug Candidates
The Lead Discovery Center GmbH (LDC) and Johnson & Johnson Innovation Ltd., will collaborate to identify and accelerate innovative drug candidates for the treatment and…
Recipharm Completes Acquisition; Broadens Development Capabilities
Recipharm recently announced that it has completed the acquisition of OnTarget Chemistry in Uppsala, Sweden. OnTarget Chemistry is a fast growing CRO company with a…
Taiho & Servier Enter Into Exclusive License Agreement
Taiho Pharmaceutical Co., and Servier recently announced they have entered into an exclusive license agreement for the development and commercialization of TAS-102 (non-proprietary names: trifluridine…
FDA Awards Isarna Orphan Drug Designation
Isarna Therapeutics recently announced that the Food and Drug Administration (FDA) has granted orphan drug designation for ISTH0036, a locked nucleic acid-modified antisense oligonucleotide, for…
Mylan Launches First Bioequivalent Alternative to Combination Asthma Therapy
Mylan N.V. recently announced it has launched the first bioequivalent alternative to GlaxoSmithKline’s Seretide Evohaler (salmeterol xinafoate/fluticasone propionate) under the brand name Sirdupla in the…
Melinta Therapeutics Announces Financing to Fund Completion of Final Phase III Study
Melinta Therapeutics recently announced the successful completion of a $67-million Series 4 equity financing. Malin Corporation plc led the round and was joined by other…